Using orthotopic patient-derived xenografts (PDXs) of Her2+ BCBMs, Ni et al. showed that combined inhibition of PI3K and mTOR with BKM120 and everolimus results in durable tumor regression [88]. Here, ERBB2 is linked to neoplasm.